Alico, Inc. Announces Fiscal Year 2014 Second Quarter

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Alico, Inc. Announces Fiscal Year 2014 Second Quarter Dividend

FORT MYERS, Fla., Dec. 19, 2013 (GLOBE NEWSWIRE) -- Alico, Inc. ("Alico") (Nasdaq: ALCO ), an American agribusiness and land management company, announced that its Board of Directors, at a meeting held on December 18, 2013, declared a second quarter cash dividend in the amount of $0.12 per share on its outstanding common stock. The dividend is to be paid to shareholders of record as of March 31, 2014, with payment expected on April 14, 2014.

About Alico

Alico, Inc. ("Alico") is an American agribusiness and land management company built for today's world and known for its legacy of achievement and innovation in citrus, sugar, cattle and resource conservation. We own approximately 130,800 acres of land in six Florida counties (Alachua, Collier, Glades, Hendry, Lee and Polk). Our principal lines of business are citrus groves, improved farmland including sugar cane, cattle ranching and conservation, and other operations which includes rock mining. Our mission is to create value for our customers, clients and shareholders by managing existing lands to their optimal current income and total returns, opportunistically acquiring new agricultural assets and producing high quality agricultural products while exercising responsible environmental stewardship. Learn more about Alico (Nasdaq: ALCO ) at www.alicoinc.com or follow Alico on  Facebook  and  Twitter .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based on Alico's current expectations about future events and can be identified by terms such as "expect," "may," "anticipate," "intend," "should be," "will be," "is likely to," "strive to," and similar expressions referring to future periods.

Alico believes the expectations reflected in the forward-looking statements are reasonable but cannot guarantee future results, level of activity, performance or achievements. Actual results may differ materially from those expressed or implied in the forward-looking statements. Therefore, Alico cautions you against relying on any of these forward-looking statements. Factors which may cause future outcomes to differ materially from those foreseen in forward-looking statements include, but are not limited to: changes in laws, regulation and rules; weather conditions that affect production, transportation, storage, import and export of fresh product; increased pressure from disease, insects and other pests; disruption of water supplies or changes in water allocations; pricing and supply of raw materials and products; market responses to industry volume pressures; pricing and supply of energy; changes in interest exchange rates; availability of financing for land development activities; political changes and economic crises; international conflict; acts of terrorism; labor disruptions; inability to pay debt obligations; inability to engage in certain transactions due to restrictive covenants in debt instruments; government restrictions on land use; market and pricing risks due to concentrated ownership of stock. Other risks and uncertainties include those that are described in Alico's SEC filings, which are available on the SEC's website at http://www.sec.gov . Alico undertakes no obligation to subsequently update or revise the forward-looking statements made in this press release, except as required by law.

Investor Contact: Mark Humphrey Senior Vice President and Chief Financial Officer (239) 226-2000

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ImmVira's Bladder Cancer Trials: Promising Data Revealed

Updated Category News Views 3

Tackling Bladder Cancer with Innovation In a world where every budding biotech claims they're on the cusp of revolutionizing cancer treatment, ImmVira's recent data on their oncolytic immunotherapy, MVR-T3011, stands out like a bright flash in a murky market. Presented at the prestigious European Society for Medical Oncology (ESMO) Congress 2026 in Suzhou, these updates...

Continue Reading
Resilience: From Trauma to Shielding Powerhouses

Updated Category News Views 6

A Childhood Steeped in Shadows If you think it's all Wall Street pulse for me, think again. Sometimes you stumble upon stories that hit the gut with more force than any market crash. Enter David Seymour's tale, wrapped up in his newly released autobiography from Palmetto Publishing, bearing the intriguingly gritty title: From paperboy to Secret Service Special Agent. This...

Continue Reading
ThreatLocker Launches Global AI Awareness Campaign

Updated Category News Views 4

Kicking Off with Pop Culture Pizzazz Ah, the sweet sound of a campaign that knows how to tug at the heartstrings of nostalgia. ThreatLocker has gotten creative with its latest strategy to get people buzzing about AI safety. They're unleashing a worldwide campaign themed around 'Terminator 2.' Now that's a throwback! If you've ever caught yourself wide-eyed at the edge of...

Continue Reading
Camel Group Expands Battery Portfolio at Canton Fair

Updated Category News Views 3

A Grand Display at the Canton Fair Well, here's one you don't see every day: Camel Group putting on quite the show at the 140th China Import and Export Fair, better known to us as the Canton Fair. Kicked off on October 15, 2026, in Guangzhou, this grand event paraded 'Advanced Manufacturing' as its theme, and Camel's booth was packed to the brim with what might just be...

Continue Reading
ZPMC's Wind Power and Port Projects Earn Top Honors

Updated Category News Views 1

Wind Farms and Ports: A Winning Formula National applause rings out for Shanghai Zhenhua Heavy Industries Co., Ltd. (ZPMC) as they snagged top honors in the recent National Quality Engineering Awards. It's about time folks recognized the heavy lifting these projects do in reshaping our energy and port infrastructure. Two of their standout projects walked away with...

Continue Reading
Encompass Health Expands With Texas Rehab Hospital

Updated Category News Views 6

A New Chapter in San Antonio's Healthcare Landscape Breaking ground in Texas, Encompass Health has unveiled its latest addition: a 50-bed hospital in San Antonio's Westover Hills. With sheer determination, the largest owner of inpatient rehabilitation hospitals in the U.S. has made its mark, and this isn't just any facility—at over 54,000 square feet, it's a hub for...

Continue Reading
Union Alarmtronic Joins Forces with Pye-Barker in Key Sale

Updated Category News Views 3

A Key Merger in Security Sector Here's a deal that's got the market talking: Union Alarmtronic, a stalwart in the security systems arena, has tied the knot with Pye-Barker Fire & Safety, one of the biggest names in fire protection and life safety. This move isn't just another line in the 'mergers & acquisitions' logbook; it's a strategic shift that underscores the growing...

Continue Reading
Duni Group Faces Ups and Downs in Q3 2026

Updated Category News Views 1

Navigating Choppy Waters: Duni's Third Quarter 2026 Alright, folks, let's dive into the latest from Duni Group—a company feeling the pinch but pushing through with some resilience. The third quarter 2026 report has just landed, and while some numbers are headed up, plenty are a bit of a gut punch. This isn't a crisis, but it's no smooth sailing either. Let's cut through...

Continue Reading
Groundbreaking Sale: Lani Automotive Acquires Iowa Dealership

Updated Category News Views 6

A shift in the automotive retail world takes place with Lani Automotive Group's latest move. They've just picked up their first franchised dealership, Mount Pleasant Chevrolet GMC Chrysler Dodge Jeep Ram in Iowa. It's a mouthful, sure, but it packs a punch in terms of potential growth. Why This Sale Stands Out The deal was brokered by Performance Brokerage Services, which...

Continue Reading
Marengo: Bold Moves in TMB-H Tumor Treatment

Updated Category News Views 0

A New Hope for Tough Tumors? Marengo Therapeutics is stirring up the oncology world with some intriguing Phase 2 results from their STARt-001 clinical trial, revealing invikafusp alfa's potential as a single-agent therapy. This hasn’t been a walk in the park, mind you; we're talking about dealing with TMB-H solid tumors that typically thumb their noses at immune...

Continue Reading
iv>